Media Release

SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) —


Immutep Limited

(ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, will participate in The JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022.

Presentation Details

:

Date:        Wednesday, 7 December 2022

Time:        11:20am EST

Mr. Voigt will be available for virtual one-on-one meetings during the conference. A live webcast of his presentation will be available

here

and after the meeting

under the Events page

within the Investors & Media section of Immutep’s website.

About Immutep


Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immutep’s lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website

www.immutep.com

or by contacting:

Australian Investors/Media:


Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268;


[email protected]

U.S. Media:


Tim McCarthy, LifeSci Advisors

+1 (917) 679 9282;


[email protected]